Imbed Biosciences recently announced the launch of SAM PainGuard with Lidocaine, which encompasses Surgaflex PainGuard for surgical wounds and Pelashield PainGuard for burn and trauma wound management. “Nearly 90% of…
Exact Sciences has entered into an exclusive agreement with Freenome, a biotechnology company pioneering an early cancer detection platform, the company announced recently. According to a release, Exact Sciences will…
Promega has committed to set near-term company-wide emission reductions with the Science Based Targets initiative (SBTi), the company announced recently. According to a release, this commitment begins a defined process…
Promega and Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, are partnering, the companies recently announced. According to…
Promega and Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed and reproducibility, have partnered, the companies recently announced. According to a release, the partnership will expand…
Exact Sciences‘ Oncodetect molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostic Services Program (MolDX), the company announced recently….
SHINE Technologies has entered into a strategic partnership with Standard Nuclear, a reactor-agnostic producer of TRISO nuclear fuel and radioisotope power systems, SHINE announced today. According to a release, the…
Voximetry and Medpace Core Laboratories, a full-service core laboratory, have entered a strategic partnership aimed at enhancing radiopharmaceutical clinical trials through the integration of cutting-edge dosimetry technology and comprehensive contract…
Cellectar Biosciences and Nusano, a physics company transforming the production of radioisotopes, signed a multi-year supply agreement, the company announced recently. According to a release, Nusano will provide Cellectar with…
Archeus Technologies has received FDA clearance for its Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule developed for the imaging and treatment of prostate cancer,…
